A word from the CEO
”2021 has been an exceptional and important year for
To be able to continue the commercialization of our existing products, and to develop and apply for regulatory approval for new products and markets, we have completed a new issue of 86 MSEK. Thanks to the support we received from our shareholders in the now completed share issue, we have everything in place to implement our business plan.
It’s reassuring that despite the restrictions inflicted by the COVID 19 pandemic, we see a strong recovery and growth in the oncology segment, we also saw an all-time high in sales in
Reporting period
- Net sales amounted to 5,894 (20) KSEK
- Profit after financial items amounted to -19,991 (-6,012) KSEK
- Cash flow from operating activities for the period amounted to -9,423 (-3,834) KSEK
- Earnings per share before and after dilution amounted to -0.21
(-0.08) SEK
Reporting period
Please note that
- Net sales* amounted to 11,996 (84) KSEK
- Profit after financial items amounted to -50,573 (-24,052) KSEK
- Cash flow from operating activities for the period amounted to -28,206 (-18,902) KSEK
- Earnings per share before and after dilution amounted to -0.54 (-0.33) KSEK
- Cash and cash equivalents at the end of the period amounted to 18,402 (42,064) KSEK
*Net sales for the period including
Events during the reporting period
AroCell informed about the updated operational strategy following the acquisition ofIDL Biotech AB . The Group has established a joint office in Bromma so that the operations' strengths and areas of expertise are utilized optimally, to vigorously develop and streamline the newly formed Group.
- A new study was published that examined whether the concentration of thymidine kinase 1 (TK1) in the blood early shows whether cytotoxic drugs work or not. The measurements were made with
AroCell 's TK 210 ELISA. The article is authored byBernhard Tribukait and was published in the journal Cancers, 2021.
AroCell continues to expand on the market with new distributors. The Group has signed a distributor agreement withRock Medical Ltd covering theUK andNorthern Ireland for the sale of UBC® Rapid.
AroCell 's Board of Directors proposed a fully guaranteed rights issue, which was then approved at the Extraordinary General Meeting inJanuary 2022 .
- At the end of the year,
AroCell signed a Supply and License agreement with ZECEN Biotech for the distribution of the TPS® CLIA product on all their automated platforms on the Chinese market. The registration process has been initiated withThe National Medical Products Administration (NMPA) inChina and the product is planned to be available on the Chinese market by the end of 2022.
Events after the reporting period
- A prospectus has been published for the proposed and approved rights issue.
AroCell has initiated a discussion about a collaboration withAttana AB . The collaboration aims to giveAroCell access toAttana 's extensive knowledge in quality and product development, whileAroCell 's biomarkers could eventually be used onAttana 's instruments.
- During the Extraordinary General Meeting,
AroCell 's Board was expanded with two new members,Per-Anders Abrahamsson and Max Pihlqvist.
- The outcome of the rights issue was 100% subscribed for, of which 63% with or without the support of subscription rights. The other 37% were subscribed by the issue guarantors. The Group receives approximately
SEK 86 million before deductions for issue costs.
Interim report
© Modular Finance, source